Streetbeat News

Revenues

RFIL

RF Industries (NASDAQ:RFIL) reported Q1 losses of $(0.06) per share, meeting analyst estimates, but missed revenue expectations with $13.46M against a $14.49M forecast. This represents a 26.63% decrease in sales compared to the same period last year.

Portfolio Pulse from dijoy@benzinga.com

March 18, 2024 | 8:18 pm

REYN

Reynolds Consumer Products has reaffirmed its Q1 2024 guidance, projecting net revenues of $795M-$820M and EPS of $0.21-$0.23, aligning closely with analyst estimates of $813.837M in revenue and $0.22 EPS.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:17 pm

PBM

Psyence Biomedical Ltd. (NASDAQ:PBM) welcomed a study published in Molecular Psychiatry, showing nature-derived psilocybin may be more therapeutic than synthetic versions, particularly in neuroplasticity effects. The study, not funded by Psyence Biomed, was conducted by Hebrew University. Psyence Biomed, focusing on nature-derived psilocybin for Palliative Care, is preparing for a Phase llb clinical trial targeting Adjustment Disorder in cancer patients. The U.S. Palliative Care market is expected to grow to $28.6 billion by 2030. Psyence Biomed's approach could potentially improve patient quality of life and reduce healthcare costs.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:11 pm

OPAD

OPEN

RDFN

Z

The National Association of Realtors (NAR) has reached a $418 million settlement that introduces significant changes to how agent commissions are negotiated, impacting online real estate platforms like Zillow and Redfin. The settlement, effective by mid-July 2024, ends the practice of seller's agents determining buyer's agent compensation and requires written agreements for commissions. This could pose revenue and profit challenges for Zillow and Redfin, which rely heavily on buy-side commissions. However, the settlement also removes a regulatory overhang, and companies with innovative models and technology, including Opendoor and Offerpad, are well-positioned to adapt and potentially benefit in the long term.

Portfolio Pulse from Surbhi Jain

March 18, 2024 | 7:12 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by 8 analysts in the last three months, showing a range of opinions from bullish to bearish. Recent ratings indicate a shift towards a more bullish outlook, with an average 12-month price target of $53.25, reflecting a 1.43% increase from the previous target. Analyst actions include both raises and lowers in ratings and price targets, reflecting ongoing market and company performance assessments. Mirum Pharmaceuticals, a biopharmaceutical company, focuses on therapies for rare diseases, showing significant revenue growth and strong financial indicators despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 7:00 pm

PLNT

TSN

Tyson Foods Inc (TSN) and Planet Fitness (PLNT) are facing boycott calls due to viral news stories, with Tyson accused of hiring migrant workers and Planet Fitness involved in a locker room incident. Tyson has refuted the claims, emphasizing its legal hiring practices and opposition to illegal immigration. Planet Fitness stands by its non-discrimination policy despite backlash. The impact of these boycotts on their revenue streams is uncertain, recalling Anheuser-Busch InBev's (BUD) experience with Bud Light.

Portfolio Pulse from Chris Katje

March 18, 2024 | 6:13 pm

CRL

Charles River (NYSE:CRL) has been evaluated by 7 financial analysts over the past three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $273.29, indicating an 11.42% increase from the previous target. Analysts from firms like Argus Research, Evercore ISI Group, and UBS have raised their price targets, reflecting optimism about the company's performance. Despite a recent -7.85% decline in revenue growth, Charles River maintains a strong financial performance with an 18.46% net margin and a 5.42% ROE, outperforming industry standards.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 6:01 pm

NEO

NeoGenomics (NASDAQ:NEO) received mixed analyst ratings with 4 bullish and 2 somewhat bullish out of 6 recent reviews. Analysts adjusted their price targets, leading to an average target of $20.67, up from $20.60. The company operates cancer-focused genetic testing labs and has shown a revenue growth of 12.15% as of December 31, 2023, but struggles with a net margin of -9.21% and an ROA of -0.85%. Its debt-to-equity ratio is below industry average at 0.65.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 6:00 pm

GNS

Genius Group Limited (NYSE:GNS) and OpenExO have signed a definitive merger agreement in an all-share transaction to form a global AI Education Group. This merger aims to serve a network of 100 Genius Cities and prepare 100 million students for the future. The merger, leveraging OpenExO's global community and AI-driven tools, is expected to accelerate Genius Group's growth towards achieving $1 billion in annual revenues and expanding its educational and entrepreneurial ecosystem.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 5:03 pm

PYCR

Paycor HCM (NASDAQ:PYCR) received mixed analyst ratings in the latest quarter, with 3 bullish and 1 indifferent rating. The average 12-month price target is $33.00, up from $27.00, indicating a positive sentiment shift. Paycor HCM, a provider of payroll and HCM solutions, has shown a revenue growth rate of 20.08% as of December 31, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -16.45%, ROE of -2.07%, and ROA of -0.99%.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:01 pm